These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27578760)

  • 1. Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine.
    Fletcher HA
    mBio; 2016 Aug; 7(4):. PubMed ID: 27578760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis.
    Gengenbacher M; Nieuwenhuizen N; Vogelzang A; Liu H; Kaiser P; Schuerer S; Lazar D; Wagner I; Mollenkopf HJ; Kaufmann SH
    mBio; 2016 May; 7(3):. PubMed ID: 27222470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary pyridoxine controls efficacy of vitamin B6-auxotrophic tuberculosis vaccine bacillus Calmette-Guérin ΔureC::hly Δpdx1 in mice.
    Gengenbacher M; Vogelzang A; Schuerer S; Lazar D; Kaiser P; Kaufmann SH
    mBio; 2014 Jun; 5(3):e01262-14. PubMed ID: 24895310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guérin ΔureC::hly vaccine's superior protection against tuberculosis.
    Vogelzang A; Perdomo C; Zedler U; Kuhlmann S; Hurwitz R; Gengenbacher M; Kaufmann SH
    J Infect Dis; 2014 Dec; 210(12):1928-37. PubMed ID: 24943726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial.
    Grode L; Ganoza CA; Brohm C; Weiner J; Eisele B; Kaufmann SH
    Vaccine; 2013 Feb; 31(9):1340-8. PubMed ID: 23290835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-exposure vaccination with the vaccine candidate Bacillus Calmette-Guérin ΔureC::hly induces superior protection in a mouse model of subclinical tuberculosis.
    Gengenbacher M; Kaiser P; Schuerer S; Lazar D; Kaufmann SH
    Microbes Infect; 2016 May; 18(5):364-8. PubMed ID: 26994939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manipulation of BCG vaccine: a double-edged sword.
    Singh VK; Srivastava R; Srivastava BS
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):535-43. PubMed ID: 26810060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-Generation Vaccines Based on Bacille Calmette-Guérin.
    Nieuwenhuizen NE; Kaufmann SHE
    Front Immunol; 2018; 9():121. PubMed ID: 29459859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa.
    Loxton AG; Knaul JK; Grode L; Gutschmidt A; Meller C; Eisele B; Johnstone H; van der Spuy G; Maertzdorf J; Kaufmann SHE; Hesseling AC; Walzl G; Cotton MF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27974398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A second-generation recombinant BCG strain combines protection against murine tuberculosis with an enhanced safety profile in immunocompromised hosts.
    Valencia-Hernandez AM; Zhao G; Miranda-Hernandez S; Segura-Cerda CA; Pedroza-Roldan C; Seifert J; Aceves-Sanchez MJ; Burciaga-Flores M; Gutierrez-Ortega A; Del Pozo-Ramos L; Flores-Valdez MA; Kupz A
    Vaccine; 2024 Oct; 42(24):126291. PubMed ID: 39241355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin.
    Grode L; Seiler P; Baumann S; Hess J; Brinkmann V; Nasser Eddine A; Mann P; Goosmann C; Bandermann S; Smith D; Bancroft GJ; Reyrat JM; van Soolingen D; Raupach B; Kaufmann SH
    J Clin Invest; 2005 Sep; 115(9):2472-9. PubMed ID: 16110326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tuberculosis vaccine candidate Bacillus Calmette-Guérin ΔureC::hly coexpressing human interleukin-7 or -18 enhances antigen-specific T cell responses in mice.
    Rao M; Vogelzang A; Kaiser P; Schuerer S; Kaufmann SH; Gengenbacher M
    PLoS One; 2013; 8(11):e78966. PubMed ID: 24236077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Immunogenicity of Recombinant
    Figl J; Köhler H; Wedlich N; Liebler-Tenorio EM; Grode L; Parzmair G; Krishnamoorthy G; Nieuwenhuizen NE; Kaufmann SHE; Menge C
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberculosis vaccines: beyond bacille Calmette-Guerin.
    McShane H
    Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2782-9. PubMed ID: 21893541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?
    Moliva JI; Turner J; Torrelles JB
    Vaccine; 2015 Sep; 33(39):5035-41. PubMed ID: 26319069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments.
    Dietrich G; Viret JF; Hess J
    Vaccine; 2003 Jan; 21(7-8):667-70. PubMed ID: 12531337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous Boost Following
    Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
    Front Immunol; 2018; 9():2439. PubMed ID: 30425711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6.
    Deng YH; He HY; Zhang BS
    J Microbiol Immunol Infect; 2014 Feb; 47(1):48-56. PubMed ID: 23357605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system.
    Bottai D; Frigui W; Clark S; Rayner E; Zelmer A; Andreu N; de Jonge MI; Bancroft GJ; Williams A; Brodin P; Brosch R
    Vaccine; 2015 May; 33(23):2710-8. PubMed ID: 25869896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.